Archive | November, 2023

Hot Investor Mandate: Hong Kong Life Science Venture Capital Firm Seeks Therapeutics and Medical Devices Opportunities Globally, with Focuses on Oncology, Immunology, Metabolic and CNS Diseases

9 Nov

A life sciences venture capital fund founded in 2014 with an office in Central, Hong Kong currently manages three funds with ~ $600 million assets under management, and is actively seeking investment opportunities. On average, the size of investment is $5-25M in venture rounds. The firm prefers to act as the lead investor but is also open to co-investing. The firm looks for companies located around the globe, with a preference in the US and China. The firm is actively seeking new investment opportunities.

The firm is focused on Therapeutics and Medical Devices opportunities. The core focused therapeutic areas include oncology, immunology, metabolic and CNS diseases, but the firm is also focused on new modalities and platform technologies. The firm is also interested in interventional, novel medical devices in cardiovascular, neuro-vascular & lung diseases.

The firm prefers a management team with strong scientific background and expertise, successful track records would be a plus but is not required. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: New York Based Venture Capital Firm Invests in Series A and Beyond, Looking for Healthcare Services, Digital Health and Medical Devices Companies that Targets Unmet Needs or Underserved Communities

9 Nov

A venture capital firm was founded in 2022 and based in New York, New York. Fund I of $100M USD, dedicated towards opportunities starting at Series A rounds. The typical investment size ranges from 5mm – 10mm and the firm expects to invest in 2-3 companies in the next year. The firm focuses on opportunities in the United States and territories. The firm invests in innovative healthcare companies that demonstrate the potential to increase accessibility, improve outcomes, and reduce costs, ultimately contributing to the advancement of sustainable and equitable healthcare solutions.

The firm focuses on unmet needs and underserved communities. The firm primarily looks at services, digital health, medical devices, all through a policy lens, and does not consider pharmaceuticals. Within medical devices, the firm is interested in software enabled devices in development phases. The firm is opportunistic within the digital health sector. While the firm is open to all indications, areas with unmet needs (women’s health) are of interest.

The firm does not have any requirements of the management team. The firm will both lead and co-lead investments and require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US Private Investment Firm Invests in Digital Health and Medical Technologies with Software Component, Prefers Founding Team with Both Technical and Business Expertise

9 Nov

An early-stage private investment firm is based in Silicon Valley, CA. The initial investments are typically $25,000-$100,000 and the firm can scale investments from there. The firm also provides select startups with business development support through a no-fee program. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables, and health monitoring devices. Within digital health, the firm’s  interests include: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, and Patient Adherence. The firm prefers B2B business models.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Important Deadlines Are Approaching

2 Nov

By Cameron Hurlburt, Manager of Business Development – West Coast (US), LSN

It is officially November and some key deadlines for attending Life Science Nation (LSN) ‘s flagship RESI conference, in January of the new year, RESI JPM, are approaching. LSN wants to make sure our community takes advantage of the opportunities to save, pitch, and prepare for partnering meetings to start 2024 on the right track. Mark your calendars:

1. Price Increase on November 17

Register by November 17 and save $300 with early bird rates. Join RESI JPM 2024 – the largest early-stage life sciences partnering event of the year at Marine’s Memorial Club & Hotel in San Francisco on January 9 during the annual JPM healthcare conference week. If you are fundraising, this is your chance to make compelling connections and kickstart fundraising campaign.

Register-now-button-new

2. Innovator’s Pitch Challenge Deadline is November 22

The application deadline to apply is November 22. The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. The slots are filled on a first come, first served basis so we highly encourage early application submissions!

3. Partnering Launches on December 4

Registering for RESI JPM early ensures you will be among the first attendees to access the RESI Partnering System. The RESI Partnering Platform helps you find non-traditional partners from the newest sources of capital, including family offices, foundations, academic institutions, philanthropic organizations, and some of the hottest emerging biotech and medtech companies worldwide. If you are looking to take your partnering to the next level, consider adding the premier package to increase your access to investor profiles ($500). Premier partnering grants you access to investor mandates in the LSN Investor Database, which includes direct emails to support your target list and facilitate year-round connection.

 WHAT TO EXPECT AT RESI JPM 2024

LSN will host 500+ early-stage life Science investors and strategic partners, 500+ early-stage life science start-ups & fundraising executives, and 200+ service providers including CROs/CMOs, Tech Hubs, and Regional Organizations.

There are 100+ partnering meeting slots per attendee during the 3-day hybrid conference with additional ad-hoc meeting opportunities. Registered in-person attendees have access to    14+ Investor Panels, Workshops, and Entrepreneurial Education Classes and 50+ In-person Pitch Slots with 14 Pitch Sessions in RESI Innovator’s Pitch Challenge

Have any questions? Feel free to contact us!

RESI-SF-2024-Banner-1100

Medical Device Panel at RESI JPM 2024

2 Nov

By Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

The panel recruitment for RESI JPM, taking place in-person on January 9, 2024, has exceeded our expectations, and we are happy to announce the full lineup of the Medical Devices Investors Panel. This popular RESI panel will host an insightful conversation on forward-looking trends in medical device innovations. The participating panelists are a diverse and international representation of speakers at this RESI. By bringing together active investors and strategics with various backgrounds, RESI aims to bridge the gap between investors and fundraising entrepreneurs, fostering a platform for open communications between the buy side and sell side.

Final - Medical Devices Panel JPM24

In addition to the Medical Device Panel, LSN’s investor research team has curated a program of panels, covering a wide range of topics highly relevant to early-stage life science and healthcare innovators. Each panel will feature active investors and key strategic partners to share their knowledge based on extensive industry experiences.

Some of the panels will explore various sectors of interest, such as therapeutics, or emerging areas like mental and behavioral health. Speakers will discuss their insights on the investment landscape, future trends, and opportunities specific to these sectors or indication areas. Other panels are geared towards distinct types of industry players or investment groups that play an important strategic role in the ecosystem, such as large pharmaceutical companies, health system partners, and cross-border investment groups. These panels will delve into the strategic roles these organizations play within the ecosystem, what they are looking for in the sector, things to consider, and how companies can partner with groups like themselves.
RESI-SF-2024-Banner-1100

RESI 2024 Series Media Partnership Opportunities

2 Nov

By Caitlin Dolegowski, Marketing Manager, LSN

We’d like to introduce partnering opportunities with  Life Science Nation (LSN)’s Redefining Early Stage Investments (RESI) in 2024.

LSN’s partnering conference series is the biggest in North America focusing on early-stage life science investments and strategic partnerships. We are expecting 700-1,200 attendees to participate from 5 continents.

As a media partner, you would promote and advertise LSN partnering conferences through your communication channels, and in return, LSN offers:

  • Logo featured on LSN’s Next Phase Newsletter (45,000+ readership), Tech Hub Monthly Newsletter (5,000+ readership), event websites, event program guide, and onsite signs as a media partner.
  • Quarter page ad in RESI program guide during 2024 series.
  • Unique discount code for your constituents ($100 off registration).
  • Receive a complimentary RESI pass and an additional free ticket if there are at least two (2) registrations using the discount code.
  • Two (2) posts to LSN’s LinkedIn network with the content of the partner’s choice.
  • Banner ad featured for three (3) months on Next Phase newsletters. – content provided by the company.

Media partnership isn’t just a promotional tool for publicity and customer loyalty, it can also be expected to generate goodwill and awareness at the RESI conference series. LSN makes media sponsorship as convenient as possible, connecting your constituents with valuable resources. Here are a few examples:

  • Include the LSN logo on your conference website(s) as a media partner.
  • Include the RESI conference with a unique discount on your event calendar.
  • Two (2) email blasts to your network promoting RESI conferences or Two (2) posts to your LinkedIn (or similar social media) network with content provided by LSN.
  • Banner ad featured for three (3) months of your publication newsletter with content provided by LSN.

Thank you for your consideration. If you have any questions or want to start the media partnership today, please contact Caitlin Dolegowski, Marketing Manager at Life Science Nation.

RESI-SF-2024-Banner-1100

Hot Investor Mandate: VC Firm in Japan Invests Up to $10M in Early-Stage Life Science Companies Across the Globe, Open to All Therapeutic Modalities

2 Nov

A venture capital firm in Japan invests in life science, biotech, IT and software, and agriculture. Currently, the firm manages two funds: one fund which funds later stage companies, and another fund which is an open innovation fund to support the creation of companies and early-stage startups. The firm will also support company creation and sales in Japan as well as overseas. In total, the firm has about $400M to invest from, with $5M-10M as a typical check size per round and the same amount reserved for future follow-on investments. The firm is open to investing in all financial rounds and all sectors of life science and biotech. The firm invests globally.

The firm invests in all sectors of life science and biotech including, but not limited to, therapeutics, diagnostics, medical devices, digital health, etc. across all stages of development, focusing on early stage. Within therapeutics, the firm is open to investing in all modalities including novel biologics (i.e. cell & gene therapy). The firm is also open to all indications including orphan diseases.

The firm does not have specific management team requirements, however the firm will take a board or observer seat. The firm is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.